---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-149141"
form_type: "8-K/A"
ticker: "ELVN"
cik: "0001672619"
company_name: "Enliven Therapeutics, Inc."
filed_at: "2024-05-29T23:59:59+00:00"
generated_at: "2026-06-01T07:42:19.339236+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.2
calibrated_materiality_score: 0.2
confidence: "high"
source: SEC EDGAR
---

# Enliven Therapeutics appoints director Lori Kunkel to Nominating Committee

## Summary
- Dr. Lori Kunkel appointed to Nominating and Corporate Governance Committee effective May 29, 2024.
- Her board appointment was reported April 9, 2024; committee role now determined.
- Appointment follows recommendation of the Committee.

## SEC filing metadata
- accession: 0001193125-24-149141
- form_type: 8-K/A
- ticker: ELVN
- cik: 0001672619
- company_name: Enliven Therapeutics, Inc.
- filed_at: 2024-05-29T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.2
- calibrated_materiality_score: 0.2
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1672619/000119312524149141/0001193125-24-149141-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1672619/000119312524149141/d816859d8ka.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-149141
- JSON: https://secwatch.observer/filing/0001193125-24-149141.json
- Plain text: https://secwatch.observer/filing/0001193125-24-149141.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.